Sleuth for Reporters

Biopharma insights you can publish

Find new angles and add context for your readers, with the same knowledge base and analysts top pharma and biotech companies use for their biggest decisions.

Sleuth’s data has appeared in

Take your idea from hunch to headline

Trace deal activity, map a competitive landscape, or check a number before you print it. Sleuth’s analysts turn your question into sourced data you can use, on your deadline.

On your deadline

Send the question in the morning and get a sourced count, list, or chart back the same day.

Over weeks, with you

For a bigger story, the analysts work the question with you until the data shows what’s happening, with a source for every row.

Before publication

Read select Sleuth Intelligence reports before they go public, with time to ask questions and find your own angle.

On the record

Talk to Sleuth’s cofounder and analysts about what the data shows, and what it doesn’t.

Bring us the question behind the headlines

A question can lead to a sourced dataset, a chart, a competitive landscape, or an on-the-record interview with a Sleuth analyst, depending on the story and your deadline.

How crowded is this target or modality?

How quickly did competitors follow a major clinical result?

What does a new trial result change in the competitive landscape?

Where is deal activity speeding up, and what’s behind it?

Which assets are still unpartnered in an indication or mechanism?

Custom Trackers

A tracker for the companies on your beat

Tell Sleuth what you cover and what you want to watch, and Sleuth builds a tracker around it, with every row linked to its source. It’s updated after each company reports earnings, or whenever you ask.

You choose what it follows

A set of companies, a target, a modality, or an indication.

You choose what it tracks

Pipeline changes, approvals and filings, readouts, new trials, deals, or the catalysts companies guide to.

The programs behind every count

Click a count to see the programs behind it and where each one came from.

Sleuth analyses in the news

Reporters at the Wall Street Journal, the Financial Times, Fierce Biotech, STAT, and BioSpace have built stories on Sleuth’s data.

Fierce Biotech

As ADC king Enhertu rewrites HER2 breast cancer care, the hunt for what comes next is barely out the gate

Sleuth mapped all 276 HER2-targeted ADCs in development for Fierce, from their payloads to where they come from, and found only 20 trials enrolling HER2-positive breast cancer patients after a HER2 ADC. One is a Phase 3 after Enhertu.

“There should be earlier recognition in the industry about this type of commercial dynamic.”

Andrew Pannu

Andrew Pannu

Request access to get started

Tell us about your beat and publication. We’ll follow up to work out your first question.

What happens next

1

Tell us your beat and what you’re working on.

2

Sleuth follows up to work out your first question.

3

The analysts build the data, chart, or tracker for your story, on your deadline.

Run your own analysis on any question in biopharma

Set up in Claude, ChatGPT, or Copilot